VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling
Key Highlights
- ➤VivoSim Labs (VIVS) extends NAMkind platform into liver and intestinal efficacy testing
- ➤MASH model uses patient-derived cells to measure fibrosis and liver function over 14 or 21 days
- ➤IBD model includes twelve ulcerative-colitis and Crohn’s-disease donors with donor-specific readouts
- ➤Platform adds pharmacodynamic and target-biomarker profiling alongside functional efficacy measurements
- ➤VivoSim says disease models could more than double its addressable market
Expert Statements
Keith Murphy, Executive Chairman of VivoSim Labs
“Toxicology is the core of our business today, and it will remain a core service”
Keith Murphy, Executive Chairman of VivoSim Labs
“Our customers often need help with whether a candidate is likely to work, because that is where many drugs fall short in the clinic.”
Keith Murphy, Executive Chairman of VivoSim Labs
“Disease models let us address that question on the same human tissue platform we already use for safety, but leveraging patient-derived diseased cell sources so a customer can learn more before committing a program to clinical trials.”
Keith Murphy, Executive Chairman of VivoSim Labs
“We believe disease models could more than double our addressable market.”
Amar Sethi, M.D., Ph.D., Chief Scientific Officer of VivoSim Labs
“By leveraging patient-derived donor tissues, our disease platforms preserve the complex multiomic signatures and heterogeneous phenotypes seen in real-world clinical populations,”
Amar Sethi, M.D., Ph.D., Chief Scientific Officer of VivoSim Labs
“Crucially, we can now evaluate candidate compounds not only for primary disease endpoints like fibrosis and barrier repair, but also for target-specific pharmacodynamic biomarkers.”
Amar Sethi, M.D., Ph.D., Chief Scientific Officer of VivoSim Labs
“This dual capability allows drug developers to confirm both functional human efficacy and underlying drug mechanism on the exact same platform before entering clinical trials.”
SAN DIEGO, Oct. 21, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety and efficacy, today announced that it is extending its human tissue platform beyond toxicology, the core of its business today, with efficacy testing services built on NAMkind™ disease models of the liver and intestine. The disease models are built with cells from patient donors, so they carry features of the disease itself. Drug developers can measure whether a candidate acts on those disease features in human tissue before it enters clinical trials. VivoSim offers efficacy testing alongside toxicology on its liver and gastrointestinal (GI) models.
The move builds on demonstrated disease model excellence already demonstrated. Its intestinal efficacy platform, built in part from cells of patients with ulcerative colitis or Crohn’s disease, received a “Poster of Distinction” award at Digestive Disease Week in May 2025, in work showing that the platform responds to clinically used therapeutics. VivoSim has also used its human disease models to identify new molecular targets that drive inflammatory bowel disease (IBD) and to explore how known drugs act.
Get started
Create a free account to read the full story.